Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval - Reuters
Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval Reuters
🎗️
Онкология
🎗️Лента новостей
Онкология
FDA approves breakthrough pancreatic cancer drug proven to extend survival - Washington Examiner
FDA approves breakthrough pancreatic cancer drug proven to extend survival Washington Examiner
🎗️
Онкология
Rasonque's 60% Survival Benefit: What It Means for Oncology Pipelines - PharmTech.com
Rasonque's 60% Survival Benefit: What It Means for Oncology Pipelines PharmTech.com
Онкология
Rasonque earns FDA approval for pancreatic cancer
The FDA has approved a first-in-class targeted therapy for adults with metastatic pancreatic adenocarcinoma. Daraxonrasib (Rasonque, Revolution Medicines), an RAS inhibitor, received approval for patients who previously received at least one prior line of systemic therapy and are not candidates for multiagent systemic…
🎗️
Онкология
Himanshu Varshney: From Breast Cancer Research to ASCO Breakthrough 2026 Recognition - Oncodaily
Himanshu Varshney: From Breast Cancer Research to ASCO Breakthrough 2026 Recognition Oncodaily
Онкология
FDA approves pancreatic cancer drug taken by Ben Sasse in clinical trials, made available in Omaha - WOWT
FDA approves pancreatic cancer drug taken by Ben Sasse in clinical trials, made available in Omaha WOWT
Онкология
Statement from the Pancreatic Cancer Action Network on the U.S. Food And Drug Administration’s Approval of Rasonque™ (daraxonrasib) - Pancreatic Cancer Action Network
Statement from the Pancreatic Cancer Action Network on the U.S. Food And Drug Administration’s Approval of Rasonque™ (daraxonrasib) Pancreatic Cancer Action Network
Онкология
FDA Approves Rasonque™ (daraxonrasib) - Pancreatic Cancer Action Network
FDA Approves Rasonque™ (daraxonrasib) Pancreatic Cancer Action Network
🎗️
Онкология
Sunvozertinib Moves Into the First-Line Setting for EGFR Exon 20 NSCLC - Oncogene Cancer Research - Oncodaily
Sunvozertinib Moves Into the First-Line Setting for EGFR Exon 20 NSCLC - Oncogene Cancer Research Oncodaily
Онкология
FDA approves ‘game-changing’ pancreatic cancer drug - NBC News
FDA approves ‘game-changing’ pancreatic cancer drug NBC News
Онкология
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber | Newswise - Newswise
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber | Newswise Newswise
🎗️
Онкология
FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease - WSJ
FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease WSJ
Онкология
Q&A: Proposed physician fee schedule builds on efforts to sustain primary care
CMS recently issued its proposed 2027 Medicare Physician Fee Schedule. The proposed schedule includes a 0.75% increase to the qualifying alternative payment model (APM) conversion factor and a 0.25% increase to the nonqualifying APM conversion factor. But because the Working Families Tax Cut Act provided a 1-year…
🎗️
Онкология
Michelle Mitchell OBE: New Treatment Helps Patients with Rectal Cancer Avoid Major Surgery and Side Effects - Oncodaily
Michelle Mitchell OBE: New Treatment Helps Patients with Rectal Cancer Avoid Major Surgery and Side Effects Oncodaily
